Evidence map›Paper›PMID 31369608›Full record

ArticlePloS one2019

Determinants of shingles vaccine acceptance in the United Kingdom.

Hélène Bricout, Laurence Torcel-Pagnon, Coralie Lecomte, Mariana F Almas, Ian Matthews, Xiaoyan Lu, Ana Wheelock, Nick Sevdalis

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Hélène BricoutSanofi Pasteur, LYON, France.
Laurence Torcel-PagnonSanofi Pasteur, LYON, France.
Coralie LecomteIQVIA, Ouen cedex, France.
Mariana F AlmasIQVIA, Berkshire, United Kingdom.
Ian MatthewsMSD Ltd, Maidenhead, United Kingdom.
Xiaoyan LuMSD Vaccins, LYON, France.ORCID 0000-0002-5592-7239
Ana WheelockDepartment of Surgery and Cancer, National Institute for Health Research Imperial Patient Safety Translational Research Centre, Imperial College London, London, United Kingdom.ORCID 0000-0003-0855-7252
Nick SevdalisCentre for Implementation Science, King's College London, London, United Kingdom.
Sanofi (France) · FRIQVIA (France) · FRIQVIA (United Kingdom) · GBKing's College London · GBNational Institute for Health Research · GB

Funding

Department of Health
6 · The paper itself

Abstract

backgroundThe United Kingdom (UK) was the first European country to introduce a national immunisation program for shingles (2013-2014). That year, vaccination coverage ranged from 50 to 64% across the UK, but uptake has declined ever since. This study explored determinants of the acceptance of the shingles vaccine in the UK.

methodsVaccinated and unvaccinated individuals, who were eligible for the last catch-up cohort of the 2014-2015 shingles vaccination campaign, were identified using the Clinical Practice Research Datalink (the National Health Service data research service) and invited to participate by their general practitioner (GP). An anonymised self-administered questionnaire was developed using the Health Belief Model as a theoretical framework, to collect data on demographic and socio-economic characteristics, health status, knowledge, influences, experiences and attitudes to shingles and the shingles vaccine. Multivariable logistic regression was used to identify the factors associated with vaccination. Physicians' views concerning perceived barriers to vaccination were also assessed.

resultsOf the 2,530 questionnaires distributed, 536 were returned (21.2%) from 69 general practices throughout the UK. The majority of responders were female (58%), lived in care homes (56%) and had completed secondary or higher education (88%). There were no differences between vaccinated and unvaccinated responders. Being offered the shingles vaccine by a GP/nurse (odds ratio (OR) = 2.3), and self-efficacy (OR = 1.2) were associated with being vaccinated (p<0.05). In contrast, previous shingles history (OR = 0.4), perceived barriers to vaccination (OR = 0.7) and perceived control of the disease (OR = 0.7) were associated with not being vaccinated against shingles (p<0.05). Less than half (44.0%) of GPs were aware of the local communication campaigns regarding shingles and the shingles vaccine.

conclusionsSocio-psychological factors largely influence shingles vaccination acceptance in this study. The results add to existing evidence that healthcare providers (HCPs) have a pivotal role against vaccine hesitancy. Campaigns focusing on GPs and accessible information offered to eligible members of the public can further enhance shingles vaccine uptake.

Indexed as

Health Knowledge, Attitudes, PracticeAgedCohort StudiesFemaleHerpesvirus 3, HumanHerpes ZosterHerpes Zoster VaccineHumansImmunization ProgramsMalePatient Acceptance of Health CareUnited KingdomVaccinationHerpes Zoster Vaccine

Identifiers

PMID31369608
PMCPMC6675065
OpenAlexW2964612001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.